Calidi Biotherapeutics, Inc. Common Stock (CLDI)

As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

U.S. stock futures advanced on Wednesday after ending on a mixed note on Tuesday. Futures of major benchmark indices were trading higher.

Calidi Biotherapeutics shares are trading lower by 12.4% Wednesday. The company announced a $2 million registered direct offering at $1.00 per share.

Shares of The AES Corporation (NYSE:AES) rose sharply in pre-market trading following reports the company has received takeover interest.

Calidi Biotherapeutics (NYSE: CLDI) surged 39.47% after hours Tuesday, following renewed investor interest in its innovative cancer treatment developments.

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.

After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Calidi Biotherapeutics shares are trading lower by 32% during Friday's session. The company priced its public offering of 5 million shares of common stock at $0.85 per share.

CLDI stock results show that Calidi Biotherapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Calidi Biotherapeutics shares are trading lower by 14.3% during Monday's session. The company announced a 1-for-10 reverse stock split.